drugset
drugset / Trial / NCT00867087

Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma

NCT00867087 ↗

Phase 2 Completed 64 enrolled Pfizer UCB Pharma · collab
Non-randomizedOpen-labelTreatment

Summary

The purpose of this study is to evaluate inotuzumab ozogamicin in combination with rituximab prior to an autologous stem cell transplant (aSCT) in patients with relapsed/refractory diffuse large B-cell Non-Hodgkin's lymphoma.

Timeline

Start
2009-06-08
Primary completion
2012-10-31
Completion
2012-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Inotuzumab Ozogamicin Monoclonal antibody 1.8 mg/m2 Intravenous
Background Rituximab Monoclonal antibody 375 mg/m2 Intravenous

Indications

large B-cell lymphoma